CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 115 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.06 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $1,083,000 | -96.5% | 130,332 | -96.9% | 0.00% | -100.0% |
| Q3 2019 | $30,992,000 | -16.8% | 4,199,351 | +26.5% | 0.01% | -12.5% |
| Q2 2019 | $37,257,000 | +5.1% | 3,320,557 | +0.7% | 0.01% | 0.0% |
| Q1 2019 | $35,451,000 | -12.3% | 3,297,775 | +23.2% | 0.01% | -20.0% |
| Q4 2018 | $40,433,000 | +314.7% | 2,677,658 | +408.0% | 0.01% | +400.0% |
| Q3 2018 | $9,751,000 | +8.0% | 527,102 | +33.4% | 0.00% | 0.0% |
| Q2 2018 | $9,028,000 | -24.3% | 394,992 | -5.8% | 0.00% | -33.3% |
| Q1 2018 | $11,930,000 | +985.5% | 419,352 | +705.7% | 0.00% | – |
| Q4 2017 | $1,099,000 | +30.5% | 52,050 | +12.2% | 0.00% | – |
| Q3 2017 | $842,000 | +238.2% | 46,376 | +189.0% | 0.00% | – |
| Q2 2017 | $249,000 | -97.4% | 16,045 | -97.9% | 0.00% | -100.0% |
| Q1 2016 | $9,663,000 | -38.1% | 749,055 | 0.0% | 0.00% | -25.0% |
| Q4 2015 | $15,611,000 | – | 749,055 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 5,803,700 | $25,130,000 | 0.91% |
| Altium Capital Management LP | 663,800 | $2,874,000 | 0.79% |
| Rubric Capital Management LP | 2,406,449 | $10,420,000 | 0.49% |
| RTW INVESTMENTS, LP | 6,029,700 | $26,109,000 | 0.38% |
| Orbimed Advisors | 3,214,509 | $13,919,000 | 0.18% |
| TANG CAPITAL MANAGEMENT LLC | 152,345 | $660,000 | 0.13% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 980,085 | $4,244,000 | 0.12% |
| Point72 Asset Management, L.P. | 6,303,025 | $27,292,000 | 0.11% |
| Sender Co & Partners, Inc. | 40,720 | $176,000 | 0.09% |
| Manteio Capital LLC | 15,067 | $65,000 | 0.08% |